BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ATx08-001: Phase II data

A double-blind, U.S. Phase II trial in 61 patients showed that twice-daily 2.5 and 7.5 mg oral ATx08-001 each met the primary endpoint of significantly reducing mean pain intensity scores from baseline to week 1 vs. placebo (p<0.05 for...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >